Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This phase III trial is evaluating how effective 4-weekly injections of the drug Eplontersen, compared with a placebo, is in people with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Status : Recruiting
This phase III trial is comparing the effectiveness of two targeted therapies as a first line treatment for newly diagnosed Acute Lymphoblastic Leukaemia (ALL) in combination with reduced-intensity chemotherapy
This Phase III study is evaluating the effectiveness of tafamidis as a treatment for transthyretin cardiomyopathy
This phase I/II study is trying to understand how safe and effective treatment with a combination of targeted therapies (mosunetuzumab and tiragolumab), with or without immunotherapy (atezolizumab), is in people with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma who have received some prior treatment
This Phase II trial is trying to understand the effect of chemotherapy (obinutuzumab and atezolizumab) with or without radiotherapy in people with advanced follicular lymphoma
This phase I/II trial is evaluating the effectiveness of a new targeted therapy (KRT-232) combined with another targeted therapy (acalabrutinib) in people with relapsed or refractory diffuse large B-cell lymphoma and chronic lymphocytic leukaemia
This Phase III trial is evaluating the effectiveness of targeted therapy (tafasitamab), compared with a placebo, is when combined with other cancer drugs (lenalidomide and rituximab) in people with relapsed or refractory follicular lymphoma or marginal zone lymphoma
This phase Ib/II trial is trying to understand how safe and effective a combined treatment of two targeted therapies (TL-895 and KRT-232) is in adults with FLT3 mutated Acute Myeloid Leukaemia
This phase III trial has been designed to evaluate the addition of two cancer treatments (venetoclax in combination with azacitidine) to standard care, compared with standard care on its' own as a maintenance therapy for adult's with acute myeloid leukaemia (AML)
This phase II trial is trying to understand how safe and effective a targeted therapy (nemtabrutinib) is in people with blood cancers
Looking for a trial? Use the search functionality to find the trial you are finding.